ARTICLE | Emerging Company Profile
858: Versant’s second start-up targeting RNA-modifying proteins
Emerging Company Profile: Building on a predecessor epitranscriptomics company, 858 brings together VCs and familiar team
September 21, 2021 12:01 PM UTC
858 Therapeutics, the newest company targeting RNA-modifying proteins for oncology, will bring together a predecessor company, a veteran management team, and a deep-pocketed syndicate led by founding investor Versant Ventures.
San Diego-based 858 Therapeutics Inc. is the fifth company led by a team that has already produced a series of exits for Versant. The group reunited after the 2018 sale of Jecure Therapeutics Inc., which was developing NLRP3 inhibitors, to the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY)...